CIK cells

BIOLOGICAL4 trials

Conditions

AnemiaAutologous Hematopoietic Stem Cell TransplantBone Marrow Transplant FailureClear Cell Renal Cell CarcinomaLeukemiaLeukemia, MyeloidMultiple MyelomaMyelodysplastic Syndromes (MDS)

Phase 1

Post-transplant Autologous Cytokine-induced Killer (CIK) Cells for Treatment of High Risk Hematologic Malignancies

CompletedNCT00477035

Sally AraiLeukemia, Multiple Myeloma

Start: 2006-05-31End: 2011-03-31Updated: 2017-01-11

Phase 2

Post T-plant Infusion of Allogeneic Cytokine Induced Killer (CIK) Cells as Consolidative Therapy in Myelodysplastic Syndromes/Myeloproliferative Disorders

CompletedNCT01392989

Everett MeyerAnemia, Bone Marrow Transplant Failure, Leukemia, Myeloid +3

Start: 2011-03-31End: 2017-03-19Updated: 2019-05-07

Study of PD-1 Inhibitor Combination With Autologous Cell Immunotherapy in the Metastatic Renal Cell Carcinoma

NCT03987698

Tianjin Medical University Cancer Institute and HospitalClear Cell Renal Cell Carcinoma, Renal Cell Carcinoma

Start: 2019-06-01End: 2022-06-01Target: 90Updated: 2020-07-07

Unknown Phase

Evaluation of the Safety of Cytokine-Induced-Killer Cells During Early Transplant Period of Autologous Hematopoietic Stem Cell Transplant Recipients.

CompletedNCT07692607

LucasBioAutologous Hematopoietic Stem Cell Transplant

Start: 2022-03-28End: 2026-03-17Updated: 2026-07-09

Related Papers

Donor-Derived Cytokine-Induced Killer Cell Infusion as Consolidation after Nonmyeloablative Allogeneic Transplantation for Myeloid Neoplasms

Biology of Blood and Marrow Transplantation2019-04-0222 citations

Non-myeloablative allogeneic hematopoietic cell transplantation following fludarabine plus 2 Gy TBI or ATG plus 8 Gy TLI: a phase II randomized study from the Belgian Hematological Society.